83 reports

REST OF THE WORLD KIDNEY CANCER DRUG MARKET 2014-2022 ($MILLION) LIST OF FIGURES ##.

  • Cancer
  • Pathology
  • Renal Cancer
  • Therapy
  • World
  • Global Kidney Cancer Drugs Market
  • Global Kidney Cancer Drugs Market

About Kidney Cancer Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection...

  • Renal Cancer
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.

" Target Atlas in Renal Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline information covering commercial developments of molecular drug targets in renal cancer from companies pl

  • Cancer
  • Renal Cancer
  • CHAPTER III KIDNEY CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • CHAPTER III KIDNEY CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS

China’s demand for Kidney Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports,...

  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

Until 1980’s, the treatment of kidney cancer included surgical removal of the kidneys.

  • Renal Cancer
  • Therapy
  • United States
  • World
  • Market Size
  • Top 20 Countries with Highest Incidence of Kidney Cancer in 2012; Women
  • Top 20 Countries with Highest Incidence of Kidney Cancer in 2012; Both Sexes

Renal cell carcinoma (RCC), also known as kidney cancer or renal adenocarcinoma, is the most common type of kidney cancer in adults. It occurs at an average age of 64 years. RCC is a disease which develops in the lining of the kidney tubules and grows into a mass or tumor. It accounts for approximately 3 percent of adult malignancies and 90...

  • Renal Cancer
  • Argos Therapeutics, Inc.
  • AstraZeneca PLC
  • AVEO Oncology
  • Bristol-Myers Squibb Company
  • Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes,
  • presents the temporal trends in the age-adjusted incidence rate of kidney cancers in the

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common...

  • Renal Cancer
  • China
  • Japan
  • United States
  • Forecast
  • TRENDS IN THE FIVE-YEAR RELATIVE SURVIVAL (%) OF KIDNEY CANCERS IN THE 8MM, BOTH SEXES,
  • presents the temporal trends in the age-adjusted incidence rate of kidney cancers in the

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023 Summary Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will...

  • Renal Cancer
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • Roche Group
  • The following is the list of drugs in phase 2 or phase 3 development for renal cancer-related indications.
  • Forecast

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating...

  • Renal Cancer
  • World
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Rexahn Pharmaceuticals, Inc.
  • CHAPTER III KIDNEY CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Market Size

This study focuses on China’s Kidney Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....

  • Renal Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Renal Cancer Treatment: Industry Analysis, R& D Trends and World Market Forecasts 2015-2025 Table of Contents ##.

  • Cancer
  • Renal Cancer
  • Therapy
  • World
  • Market Size
  • CHAPTER IV KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
  • Chapter IV

This study focuses on China’s Kidney Cancer Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the...

  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

Around ##% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms’ tumor (nephroblastoma).

  • Cancer
  • Renal Cancer
  • European Union
  • Japan
  • United States

Renal cell cancer

4546 5000 3864
  • RCC IS THE MOST COMMON TYPE OF KIDNEY CANCER
  • EXTRACTING INCIDENCE RATE DATA FOR JAPAN, FRANCE, SPAIN, AND THE UK

Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents. This report addresses the following questions: - What factors are contributing to the increase in RCC incidence across the...

  • Renal Cancer
  • European Union
  • Japan
  • North America
  • United States

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H## 2018 Table of Contents ## Introduction ## Kidney Cancer (Renal Cell Cancer) - Overview ## Kidney Cancer (Renal Cell Cancer) - Therapeutics Development ##

  • Cancer
  • Pathology
  • Renal Cancer

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor.

  • Cancer
  • Pathology
  • Renal Cancer
  • Therapy
  • Product Initiative
  • 25 May 2012
  • COMPANY PRESS RELEASES RELATED TO VOTRIENT

Description “Oncology drug report - Votrient - pazopanib - 2009-2015 analysis; 2016-2021 expectations” is a comprehensive report on multi-tyrosine kinase inhibitor targeted therapy drug Votrient’s sales analysis. The report gives an analysis of the historical annual sales (from 2009-2015), historical quarterly sales (Q4-2009...

  • Renal Cancer
  • United States
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients
  • Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer

Summary Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed...

  • Hepatitis
  • Renal Cancer
  • United States
  • Company
  • Exelixis, Inc.
  • JUN 12, 2017: SCOTLAND FIRST IN UK TO MAKE CABOMETYX (CABOZANTINIB) ROUTINELY AVAILABLE FOR INDIVIDUALS LIVING WITH ADVANCED KIDNEY CANCER
  • MELANOMA

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2017 Summary BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine...

  • Renal Cancer
  • United States
  • World
  • Product Initiative
  • Exelixis, Inc.

Kidney Cancer - Pipeline Review, H## 2015 Table of Contents Table of Contents ## Introduction ## Kidney Cancer Overview ## Therapeutics Development ## Kidney Cancer - Therapeutics under Development by Companies ## Kidney Cancer - The

  • Cancer
  • Pathology
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • 04/21/2017: ARMO BIOSCIENCES ANNOUNCES CLINICAL DATA PRESENTATION FOR IMMUNOTHERAPY AM0010 AT THE 12TH EUROPEAN INTERNATIONAL KIDNEY CANCER SYMPOSIUM

Summary ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs.The company develops anti-programmed cell death protein 1 checkpoint inhibitors and other therapeutic cytokines. Its portfolio of pipeline drug candidates includes AM0010, AM0015, AM0012 and AM0001.ARMO...

  • Pharmaceutical
  • Renal Cancer
  • United States
  • Company
  • ARMO Biosciences, Inc.
  • 04/21/2017: ARMO BIOSCIENCES ANNOUNCES CLINICAL DATA PRESENTATION FOR IMMUNOTHERAPY AM0010 AT THE 12TH EUROPEAN INTERNATIONAL KIDNEY CANCER SYMPOSIUM

Summary ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs.The company develops anti-programmed cell death protein 1 checkpoint inhibitors and other therapeutic cytokines. Its portfolio of pipeline drug candidates includes AM0010, AM0015, AM0012 and AM0001.ARMO...

  • Pharmaceutical
  • Renal Cancer
  • United States
  • Company
  • ARMO Biosciences, Inc.
  • 04/21/2017: ARMO BIOSCIENCES ANNOUNCES CLINICAL DATA PRESENTATION FOR IMMUNOTHERAPY AM0010 AT THE 12TH EUROPEAN INTERNATIONAL KIDNEY CANCER SYMPOSIUM

Summary ARMO Biosciences Inc (ARMO Biosciences) is an immuno-oncology company that develops tumors treatment drugs. The company develops anti-programmed cell death protein 1 checkpoint inhibitors and other therapeutic cytokines. Its portfolio of pipeline drug candidates includes AM0010, AM0015, AM0012 and AM0001. ARMO Biosciences’s...

  • Pharmaceutical
  • Renal Cancer
  • United States
  • Company
  • ARMO Biosciences, Inc.
  • JUL 05, 2017: COMBO IMMUNOTHERAPY MAY HERALD NEW STANDARD OF CARE FOR KIDNEY CANCER

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017 Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 38 molecules. Out of which approximately 37 molecules...

  • Monoclonal Antibody
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • NOV 21, 2011: MOLOGEN ATTAINS GOALS OF RENAL CANCER STUDY WITH MGN1601 AHEAD OF SCHEDULE
  • FEB 03, 2014: MOLOGEN: FINAL RESULTS FROM RENAL CANCER TRIAL WITH MGN1601 PRESENTED AT ASCO GENITOURINARY CANCERS SYMPOSIUM

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2018 Summary According to the recently published report ’CD40 Ligand - Pipeline Review, H1 2018’; CD40 Ligand (T Cell Antigen Gp39 or TNF...

  • Renal Cancer
  • Therapy
  • World
  • Product Initiative
  • MOLOGEN AG
  • Nov 23, 2015: FDA approves Opdivo to treat advanced form of kidney cancer
  • Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016’, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development...

  • Renal Cancer
  • Therapy
  • United States
  • Company
  • Product Initiative
  • ULTRA-SENSITIVE ASSAY - KIDNEY CANCER
  • Ultra-Sensitive Assay - Kidney Cancer - Product Description

Summary Nanosphere, Inc. (Nanosphere) a subsidiary of Cepheid is a medical device company that develops molecular diagnostic tests for disease detection and patient treatment. The company’s products comprise verigene system, instrumentation, bloodstream infection tests, gastrointestinal infection tests, respiratory infection...

  • Biotechnology
  • Nanobiotechnology
  • Renal Cancer
  • United States
  • Nanosphere, Inc.
  • during the first six months of treatment. The results were published in New England Journal of Medicine.

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

  • Cancer
  • Oncology
  • Renal Cancer
  • Therapy
  • Novartis AG
  • Oct 22, 2015: Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer
  • Apr 26, 2016: Diplomat to Dispense CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or Summary Global Markets Direct’s, ‘Angiopoietin 1 Receptor (Endothelial...

  • Renal Cancer
  • United States
  • Company
  • Market Description
  • Exelixis, Inc.
  • JUN 12, 2017: SCOTLAND FIRST IN UK TO MAKE CABOMETYX (CABOZANTINIB) ROUTINELY AVAILABLE FOR INDIVIDUALS LIVING WITH ADVANCED KIDNEY CANCER
  • JUN 12, 2017: EXELIXIS ANNOUNCES INITIATION OF PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or Summary Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase...

  • Oncology
  • Renal Cancer
  • World
  • Product Initiative
  • Exelixis, Inc.